This is also reflected in the current use of FDA-approved biomarkers on cancer cells, such as tumor mutational burden (TMB), mismatch repair deficiency/microsatellite instability-high (MSI-H), and PD-L1 expression. This evidence concerns the gene CD274 and neoplasm.